Larimar Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Larimar Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $85.41 million for the year ending 2025.

  • Larimar Therapeutics, Inc. showed an increase of +157.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 15 years of available data (2011 to 2025), Larimar Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 5,722.2%.
  • Historical annual values: Fiscal year 2025: $85.41 million | Fiscal year 2024: $33.22 million | Fiscal year 2023: $26.75 million | Fiscal year 2022: $26.83 million | Fiscal year 2021: $70.10 million | Fiscal year 2020: $68.15 million | Fiscal year 2019: $1.01 million | Fiscal year 2018: $49.33 million | Fiscal year 2017: $40.78 million | Fiscal year 2016: $32.35 million | Fiscal year 2015: $35.60 million | Fiscal year 2014: $58.10 million | Fiscal year 2013: $35.52 million | Fiscal year 2012: $9.94 million | Fiscal year 2011: $1.47 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: